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Abstract
Background: The functional interchangeability of mammalian Notch receptors (Notch1-4) in normal and pathophysiologic
contexts such as cancer is unsettled. We used complementary in vivo, cell-based and structural analyses to compare the
abilities of activated Notch1-4 to support T cell development, induce T cell acute lymphoblastic leukemia/lymphoma (T-
ALL), and maintain T-ALL cell growth and survival.
Principal Findings: We find that the activated intracellular domains of Notch1-4 (ICN1-4) all support T cell development in
mice and thymic organ culture. However, unlike ICN1-3, ICN4 fails to induce T-cell acute lymphoblastic leukemia/lymphoma
(T-ALL) and is unable to rescue the growth of Notch1-dependent T-ALL cell lines. The ICN4 phenotype is mimicked by weak
gain-of-function forms of Notch1, suggesting that it stems from a failure to transactivate one or more critical target genes
above a necessary threshold. Experiments with chimeric receptors demonstrate that the Notch ankyrin repeat domains
differ in their leukemogenic potential, and that this difference correlates with activation of Myc, a direct Notch target that
has an important role in Notch-associated T-ALL.
Conclusions/Significance: We conclude that the leukemogenic potentials of Notch receptors vary, and that this functional
difference stems in part from divergence among the highly conserved ankyrin repeats, which influence the transactivation
of specific target genes involved in leukemogenesis.
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Introduction
Notch receptors participate in a highly conserved signaling
pathway that regulates cellular differentiation and homeostasis in a
dose- and context-dependent fashion (for review, see [1]).
Mammals express four different Notch receptors (Notch1-4), large
type I transmembrane glycoproteins composed of a series of
characteristic structural motifs. Activation of Notch receptors
normally depends on two successive types of proteolytic cleavages
(for review, see [2]). First, binding of ligands to the extracellular
domain of Notch triggers proteolytic cleavage just external to the
transmembrane domain by ADAM-type metalloproteases. This
creates a truncated membrane-tethered form of Notch that is
recognized by the gamma-secretase protease complex. Additional
cleavages by gamma-secretase free the intracellular domain of
Notch (ICN) from the membrane, allowing it to translocate to the
nucleus and form a transcriptional activation complex with the
DNA-binding factor CSL and a co-activator protein of the
Mastermind-like (MAML) family.
Structural studies have provided a model for the stepwise
assembly of the CSL/ICN/MAML transcriptional activation
complex [3,4]. The intracellular portions of Notch1-4 (ICN1-4)
contain N-terminal RAM domains, which bind CSL with
relatively high affinities [5,6,7], and 7 iterated ankyrin repeats.
Under physiologic conditions, the RAM domain likely mediates
the initial association of ICN and CSL, which enables formation of
a CSL:ANK composite surface that recruits MAMLs, an essential
event for transcriptional activation of target genes and subsequent
downstream functions [8,9].
In line with their critical role in assembly of this complex, ANK
domains are the most highly conserved part of ICN1-4, followed
by the RAM domains (summarized in Figure 1). In contrast,
sequences C-terminal of ANK are substantially more varied. At
the far C-termini of ICN1-4 are PEST degron domains that
stimulate ICN degradation. Between the ANK and the PEST
domains lies the most divergent portion of mammalian ICN1-4. In
ICN1 this region includes a strong transcriptional activation
domain (TAD), whereas the analogous region of Notch2 appears
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25645to contain a weaker TAD [10]. The same portion of Notch3 lacks
a conventional TAD, but instead is proposed to interact with an
as-of-yet unknown zinc-finger transcription factor that contributes
to the activation of specific target genes, such as Hes5 [11].
Sequences immediately C-terminal of ANK in ICN1 and ICN2
contain phosphorylation sites that may modulate function in
response to cytokines [12,13,14]. The function of the region
between ANK and PEST in ICN4 is unknown.
Although ICN1-4 differ in their transactivation of Notch-
responsive reporter genes in transient expression assays [11,15],
most direct comparisons performed to date in vivo have not
revealed functional differences. Replacement of the last 426 amino
acids of Notch2 with the same region of Notch1 (corresponding to
the seventh ankyrin repeat, the TAD, and the PEST domain) by
gene targeting results in normal mice [16], suggesting that these
portions of ICN1 and ICN2 are equivalent functionally. Of
relevance to this report, transduced ICN1 or ICN4 both induce
human hematopoietic progenitors to undergo T cell development
following transplantation into NOD/SCID mice [17].
An important pathophysiologic outcome of ICN overexpression is
neoplasia. Retroviral expression of ICN1 in hematolymphoid
progenitors is a potent inducer of murine T-ALL [18], and the
majority of human and murine T-ALLs harbor gain-of-function
mutations in Notch1 (for recent review, see ref. [19]. Feline leukemia
viruses that transduce the coding sequences for the RAM and ANK
domains of ICN2 accelerate T-ALL development [20], and
transgenic LCK-ICN3 mice develop T-ALL with high penetrance
and short latency periods [21], indicating that Notch2 and Notch3
also have leukemic potential. Recent deep sequencing studies have
identifiedacquiredmutationsthatresultindeletionoftheC-terminal
PEST domain in 10-15% of human chronic lymphocytic leukemia
(CLL) [22,23], a type of Notch1 mutation originally identified in
human T-cell acute lymphoblastic leukemia (T-ALL) [24] that
stabilizes ICN1 and enhances the transactivation of target genes in
leukemia cells. Conversely, Notch signaling has tumor suppressive
effects in the context of squamous epithelium [25,26], a finding that
emphasizes the context-dependent outcome of Notch signaling.
Notch4 was first identified as a proviral insertion site in murine
mammary tumors, and enforced expression of ICN4 contributes to
development of adenocarcinoma [27]. However, the transforming
abilities of ICN1-4 have not been compared directly in vivo in a
single cellular context, and other data suggest that ICNs have
divergent activities. For example, ICN1 and ICN2 reportedly have
opposing effects on the growth of brain tumors [28]. Thus, the
physiologic and pathophysiologic interchangeability of ICN1-4 is
an open question.
To address this issue, we compared the ability of ICN1-4 to drive
T cell development and cause T-ALL in vivo and to rescue T cell
progenitors from blockade of endogenous Notch signaling in thymic
organ culture assays. We find that while ICN1-4 all support T cell
development,only ICN1-3induce T-ALLefficiently.Tcellprogenitors
expressing ICN4 appear to be actively extinguished and disappear by 6
months post-transplantation, a phenotype resembling that caused by
‘‘hypoleukemic’’ weak gain-of-function forms of Notch1 [29]. Further,
studies performed with chimeric receptors allowed us to map the
structural basis for this difference in leukemogenicity to repeats 2–7 of
the ANK domain, which influence the ability of ICN to activate
expression of Myc, a key Notch target gene implicated in leukemo-
genesis. These studies demonstrate that the transforming activities of
Notch receptors in hematolymphoid progenitors are not equivalent,
and that this functional divergence is attributable in part to variation in
the highly conserved ANK domains.
Results
ICN1-4 Drive T cell Development in vivo and Rescue
Developing Thymocytes from the Effects of Gamma-
Secretase Inhibitors
When expressed in hematopoietic progenitors, gain-of-function
forms of Notch1 cause a CD4
+CD8
+ double-positive (DP) T cell
population to appear in the bone marrow by day 24 post-bone
marrow transplant (BMT) [18]. To begin to compare the activities
of ICN1-4 in hematopoietic cells, we transduced bone marrow
progenitors with MigRI retroviruses of equal titer, and used these
cells to reconstitute syngeneic recipient animals. On day 24 post-
BMT, the marrow of all ICN1-4 animals contained an abnormal
GFP
+ DP T cell population, whereas DP T cells were absent from
the GFP
- bone marrow cell populations of ICN1-4 animals
(Figure 2A), as well as MigRI control animals (data not shown).
Thus, ICN1-4 all drive ectopic T cell development from bone
marrow progenitors.
To further study the interchangeability of ICN1-4 in developing
T cells, we compared the ability of ICN1-4 to rescue T cell
development in thymic organ cultures treated with compound E, a
potent gamma-secretase inhibitor (GSI) that blocks T cell
development at the CD4
2CD8
2 double negative (DN) 3a stage
by inhibiting ICN1 production. In experiments conducted with
transduced fetal liver hematopoietic progenitors, ICN1-4 all
rescued DP T cell development in the presence of GSI
(Figure 2B and data not shown), indicating that each can induce
intrathymic T cell development.
ICN4 does not Induce T-ALL or Support the Growth of
Notch1-Dependent T-ALL Cells
When activated Notch isoforms are expressed in bone marrow
progenitors, the appearance of circulating DP T cells is usually a
Figure 1. ICN1-4 Sequence Homology. The numbers at right are the %identity/%overall identity and similarity for each indicated domain of ICN2,
ICN3, and ICN4 relative to ICN1, based on sequence alignments and homology calls performed by Clustal. Similarity is defined as positions with
conservative or semi-conservative substitutions. N.S. indicates no significant homology. Domain boundaries were defined based on ICN1, in which
the RAM domain and flanking C-terminal sequences span residues 1761 to 1872; the ankyrin repeat domain (ANK) spans residues 1873 to 2123; an
ANK flanking region (AFR) spans residues 2124 to 2204; the transcriptional activation domain spans residues 2205 to 2422 [10]; and the C-terminal
domain including the PEST degron spans residues 2423 to 2556.
doi:10.1371/journal.pone.0025645.g001
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ICN1-4 transduced progenitors uniformly developed circulating
GFP+ DP T cells by day 21 post-transplant. By day 124 post-
transplant, all of the ICN1, ICN2, and ICN3 animals developed
T-ALL, but ICN4 animals remained healthy and did not develop
leukemia (summarized in Table 1). At necropsy, ICN1-3 animals
showed widespread involvement of tissues by leukemic blasts,
which had immunophenotypes consistent with immature T cells
(data not shown). These leukemias were readily transplantable to
secondary recipients (summarized in Table 1).
A clue to the basis for this distinction between ICN1-3 and
ICN4 was evident in analyses of bone marrow on day 128 post-
transplant. By this time point in ICN4 animals GFP
+ cells were
markedly decreased in number, whereas the GFP
+ DP T cell
populations in ICN1-3 animals continued to expand as T-ALL
developed (Figure 3A). In contrast to ICN4 animals, GFP
+ cells
persisted indefinitely in MigRI control animals (data not shown),
suggesting that ICN4 suppresses or extinguishes cells with long-
term self-renewal capacity. Consistent with this possibility, by 180
days post-transplant ICN4 animals lacked GFP
+ Lin
2Sca1
2c-Kit
+
(LSK) bone marrow cells, a population that contains cells with
long-term self-renewing capacity [30], whereas a persistent GFP
+
LSK cell population was detectable in MigRI control animals
(Figure 3B).
LSK populations in ICN1-3 animals could not be studied
because of the development of T-ALL. Of note, however, in prior
work we observed that expression of weak gain-of-function non-
leukemogenic Notch1 alleles in murine HSCs resulted a burst of T
cell development followed by loss of GFP-positivity in the
hematolymphoid compartment and no T-ALL development
[29,31], a phenotype closely resembling that produced by ICN4.
In addition, expression of ICN1 in Rag1-/- HSCs, which do not
develop T-ALL due to defects in lymphoid development, also
Figure 2. Mammalian ICNs Induce T Cell Development in the Bone Marrow and in Fetal Thymic Organ Cultures. (A) Bone marrow cells
were analyzed by flow cytometry on day 24 post-reconstitution of lethally irradiated recipients with marrow transduced with MigRI-ICN1-4.
Representative results are shown. (B) Fetal liver hematopoietic progenitors transduced with MigRI, MigRI-ICN1, or MigRI-ICN4 were used to
reconstitute irradiated thymic lobes obtained from the same donor animals. Left hand panels: MigRI control lobes treated with vehicle (DMSO) or the
gamma-secretase inhibitor (GSI) compound E (1 microM). Right hand panels: MigRI-ICN1 and MigRI-ICN4 lobes treated with compound E (1microM).
doi:10.1371/journal.pone.0025645.g002
Table 1. Summary of Transplant Experiments Performed with
Bone Marrow Cells Transduced with ICN1-4.
ICN1 ICN2 ICN3 ICN4
# of Mice Analyzed 30 24 24 28
Mean WBC (610
3 cells/mm
3)*
Day 21 21+/232 0 +/222 0 +/231 5 +/25
Day 60 62+/255 0 +/236 9 +/221 8 +/22
Day 124 94+/291 1 0 +/268 6 +/271 9 +/22
PB GFP
+ CD4
+/CD8
+ Cells (%)*
Day 21 26+/232 0 +/232 2 +/221 4 +/22
Day 60 60+/235 0 +/245 3 +/23 ,1
Day 124 92+/248 7 +/248 2 +/25 ,1
Leukemia Induction in Secondary Recipients**
Yes Yes Yes No
*+/2 1 S.D.
**As assessed by secondary transfer of GFP
+ CD4
+/CD8
+ bone marrow cells
obtained on day 21 post-transplant.
WBC, white blood cell count; PB, peripheral blood.
doi:10.1371/journal.pone.0025645.t001
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other forms of activated Notch appear to deplete LSK populations
in reconstituted mice, possibly by inducing differentiation at the
expense of maintenance of multipotent progenitors.
T-ALL cell lines derived from Notch1-induced T-ALLs require
persistent Notch signaling for growth and survival. The murine T-
ALL cell line T6E [32] expresses a membrane tethered form of
Notch1 that requires gamma-secretase cleavage for activation and
can be rescued from GSI-induced apoptosis by retroviral
transduction of ICN1, which lies downstream of the GSI blockade.
ICN1 rescued T6E cells from GSI induced growth arrest and
apoptosis, whereas ICN4 did not (Fig. 3C and 3D). Thus, ICN4 is
also incapable of maintaining the growth of established Notch-
dependent T-ALL cells.
ANK Domains Determine Notch Receptor
Leukemogenicity
The modular nature of Notch intracellular domains and the
availability of a high-resolution structure of the ANK domain of
ICN1 [3,33] facilitated construction of chimeric ICNs, which were
used to investigate the structural basis for the functional differences
between leukemogenic ICNs and ICN4. Because the greatest
variation among ICNs is in the region C-terminal of ANK
(Figure 1), we anticipated that addition of this region of ICN1 to
the RAM-ANK domain of ICN4 would create a leukemogenic
chimera. However, the resulting chimeric polypeptide, ICN4/
ICN1-CT, created by joining of the RAM-ANK domain of ICN4
to the C-terminus of ICN1 at position J3 (Figure S1), produced an
‘‘ICN4’’ phenotype characterized by the transient appearance of
Figure 3. ICN4 does not Induce T-ALL or Rescue Notch-1-Dependent T-ALL Cells. (A) GFP+ marrow populations in mice on day 128 post-
reconstitution with marrow progenitors transduced with MigRI-ICN1-4. (B) GFP+ Lin-/Sca1-/c-Kit+ (LSK) marrow populations in mice on d180 post-
reconstitution with marrow progenitors transduced with MigRI or MigRI-ICN4. (C) T6E transduced with empty MigRI virus or MigRI-ICN1 or -ICN4
viruses were treated with the gamma-secretase inhibitor (GSI) compound E (1 microM) and monitored for growth. (D) DNA content histograms of T6E
cells transduced with ICN1 or ICN4 and treated with compound E (1 microM) for the indicated times.
doi:10.1371/journal.pone.0025645.g003
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transplantation and the absence of leukemia (data not shown).
Because the RAM domain of ICN1 is not essential for
leukemogenesis [18], we next focused on ANK, which is required
for all known physiologic and pathophysiologic Notch functions.
Biophysical differences among the recombinant ANK
domains are minimal
Recombinant human ANK1-4 proteins exhibit highly similar
circular dichroism spectra (Figure S2A). The programs CON-
TINLL [34], SELCON3 [35], and K2D [36] on the Dichroweb
server [37], yield estimates of 36–40% alpha helix for all four
molecules. Moreover, there are minimal differences in the thermal
stability of the four ANK domains, with Tm values ranging from
46–50uC for the four proteins: (ANK1 Tm=50uC; ANK2
Tm=47uC; ANK3 Tm=46uC; ANK4 Tm=50uC; Figure S2B).
These data show that the variations in primary sequence observed
in the ANK family do not translate to substantial heterogeneity in
secondary structure or domain stability. However, a comparison of
ANK1-4 surfaces based on the ANK1 crystal structure [3,33]
predicts that while the contacts involved in CSL/ANK/MAML
ternary complex formation are highly conserved, surfaces on the
convex faces of ANK domains opposite CSL/MAML contacts are
more varied (Figure S3), raising the possibility of functional
divergence among the four ANK domains.
Guided by these structural insights, we constructed an
ICN1(ANK4) chimera by swapping the ANK of NOTCH4 into
the ICN1 backbone at positions J1 and J3 (Figure S1). The
resulting ICN1(ANK4) polypeptide produced an ‘‘ICN4’’ pheno-
type in mice (Figure 4A and Table 2), indicating that the ANK
domain of ICN4 is limited in its capacity to support leukemia
induction. In contrast, ICN chimeras in which the ANK domains
of ICN2 or ICN3 were swapped into ICN1 at positions J1 and J3
were fully leukemogenic (Figure 4A; summarized in Table 2).
To assess whether this functional distinction stemmed from
differences in protein quantity, we compared the levels of
leukemogenic ICN1 and ICN1(ANK2) and non-leukemogenic
ICN1(ANK4) chimeric polypeptides in cells transduced with
retroviruses of equal titer. Western blots stained with an antibody
specific for a common epitope located in the TAD of Notch1
revealed that these forms of ICN were expressed at equal levels
(Figure 4B), suggesting that the variation in leukemogenecity stems
from qualitative differences. In parallel, we noted that these ICNs
activated a sensitive Notch reporter gene to a similar degree
(Figure 4C). Together, these findings suggested that the differences
in leukemogenic activity stem from qualitative differences in the
ability of different ANKs to activate genomic target genes.
Additional experiments were then conducted to further define
the structural variation responsible for the observed functional
differences. The greatest structural divergence among the ANKs is
in the first repeat, which is partially unstructured [3,33,38]. We
therefore constructed and tested an ICN1(ANK4r2-7) chimera
created by swapping ankyrin repeats 2–7 of ICN4 into the
backbone of ICN1 at positions J2 and J3 (Figure S1). This chimera
also produced an ‘‘ICN4’’ phenotype in mice (Figure 4A;
summarized in Table 2).
We also tested the contribution of the ANK domain to the
growth maintenance of two Notch1 ‘‘addicted’’ GSI-sensitive
murine T-ALL cell lines, T6E and G4A4. These results correlated
Figure 4. Chimeric ICN Polypeptides Containing the Notch4
Ankyrin Repeats Fail to Induce T-ALL, Despite Comparable
Activation of a Notch Reporter Gene. (A) Kaplan-Meier curves for
mice reconstituted with bone marrow progenitors expressing ICN1,
ICN1(ANK2), ICN1(ANK4), or ICN1(ANK4r2-7). (B) Western blot analysis of
U2OS cells transduced with empty MigRI virus or MigRI viruses carrying
cDNAs for the indicated ICN polypeptides. After normalization on GFP
expression, lysates were analyzed on Western blots stained with either a
rabbit polyclonal antiserum specific for the TAD of Notch1 or a
monoclonal antibody specific for GFP. (C) U2OS cells grown in 24-well
dishes were co-transfected with 1 ng or 10 ng of pcDNA3 plasmids
encoding the indicated forms of ICN, an internal control Renilla luciferase
plasmid, and an artificial Notch-responsive firefly luciferase reporter gene
plasmid. Luciferase activities were determined in triplicate 44–48 hr post-
transfection. Fold stimulations represent the normalized firefly luciferase
activity relative to that of the empty vector control, which is arbitrarily
given a value of 1. Error bars represent 1 standard deviation. ICN1(ANK2),
ICN1 backbone containing the ANK domain of Notch2; ICN1(ANK4), ICN1
backbone containing the ANK domain of Notch4; ICN1(ANK4r2-7), ICN1
backbone containing ANK repeats 2–7 of Notch4.
doi:10.1371/journal.pone.0025645.g004
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leukemogenic ANK of Notch2 supported T-ALL cell growth and
survival, whereas chimeric ICNs containing Notch4 ANK or
Notch4 ANK repeats 2–7 did not (Figure 5).
ICN Leukemogenecity Correlates with Transactivation of
Myc
Myc is a direct Notch target gene that contributes to leukemo-
genesis [39,40,41], and the failure of certain ICNs to induce T-ALL
or maintain T-ALL cell growth might therefore stem from differing
abilities to transactivate Myc. This idea was tested using the 8946 T-
ALLcellline,whichwasderivedfromamurineT-ALLinducedwith
a ‘‘doxycycline-off’’ human MYC transgene. 8946 cells are rescued
from doxycycline treatment by transduction of activated Notch1
[39], which induces expression of endogenous murine Myc.W e
observed that leukemogenic forms of ICN (ICN1 and ICN1(ANK2)
rescued the growth of 8946 cells in the presence of doxycycline,
whereas non-leukemogenic ICNs (ICN4, ICN1(ANK4), and
ICN1(ANK4r2-7)) did not (Figure 6A). None of the ICNs had any
effect on the growth of 8946 cells in the absence of doxycycline
(Figure S4). Growth rescue correlated with transactivation of the
endogenous murine Myc gene, as ICN1 and ICN1(ANK2), but not
ICN4 or ICN1(ANK4r2-7), induced Myc expression (Figure 6B). We
also noted that upregulation of endogenous Myc by ICN1 and
ICN1(ANK2) was blunted by expression of transgenic MYC
(Figure 6B). Transgenic or translocation-mediated overexpression
of Myc leads to autorepression of intact endogenous Myc loci [42,43]
through a mechanism that appears to involve polycomb family
repressors [44]; it may be that autorepression also attenuates ICN
transactivation of endogenous Myc in 8946 cells. The inability of
non-leukemogenic forms of ICN to upregulate Myc did not reflect a
generaldefectintransactivationofgenomicNotchtargetgenes,asall
ICNs tested upregulated Deltex1 (Figure 6C), and showed varying
abilities to upregulate other Notch1 target genes, such as Ptcra (pre-T
cell receptor-alpha), CD25,a n dNotch3 (Figure S5). Of note, none of
the Notch target genes were expressed in the basal state in 8946 cells
and, like Myc, showed varying degrees of suppressed responsiveness
in the presence transgenic human Myc. Thus, in the MYC-induced
8946 cell line there appears to be no selective pressure for expression
of Notch target genes, and indeed enforced Myc expression may be
associated with epigenetic changes that negate Notch’s ability to
upregulate its targets.
Discussion
These studies indicate that ICN1-4 share the capacity to drive T
cell development, but differ in leukemogenic potential. Specifical-
Table 2. Summary of Transplant Experiments with Chimeric ICNs.
Construct
# of
Mice
# with DP
T Cells
# of
T-ALLs
Mean Onset
(days)
Onset Range
(days)
Mean WBC
(10
3/mm
3)
WBC range
(10
3/mm
3)
Mean spleen
weight (mg)
Spleen weight
range (mg)
ICN1 5 5 5 62 54–70 140 29–216 0.75 0.52–0.85
ICN1(ANK2) 4 4 4 55 43–70 113 29–176 1.17 0.96–1.23
ICN1(ANK3) 3 3 3 56 43–63 161 24–320 1.17 0.4–1.26
ICN1(ANK4) 4 4 0 N/A N/A 20.5 19–23 N/A N/A
ICN1(ANK4r2-7) 4 4 0 N/A N/A 20 16–23 N/A N/A
WBC=white blood cell count; DP T cells=CD4+/CD8+ GFP+ T cells in peripheral blood on day 24 post bone marrow transplant; onset=onset of T-ALL, defined as the
appearance of symptoms (lassitude, scruffiness), physical signs (organomegaly), and an increasing number of GFP+ DP cells in the peripheral blood.
doi:10.1371/journal.pone.0025645.t002
Figure 5. Non-Leukemogenic ICN Chimeras are Defective in Growth Rescue of ‘‘Notch1-Addicted’’ T-ALL Cells. The Notch1-dependent
murine T-ALL cell lines T6E and G4A2 were transduced with empty MigRI virus or the indicated forms of ICN and monitored for growth in the
presence of the gamma-secretase inhibitor (GSI) compound E (1 microM). ICN1(A2), ICN1 backbone containing the ANK domain of Notch2; ICN1(A4),
ICN1 backbone containing the ANK domain of Notch4; ICN1(A4r2-7), ICN1 backbone containing ANK repeats 2–7 of Notch4.
doi:10.1371/journal.pone.0025645.g005
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T-ALL cell growth, despite its ability to transform cells of other
lineages, such as breast epithelial cells. Based on domain swaps, we
find that this difference in outcomes stems primarily from variation
in the highly conserved ANK domains, which appears to
selectively influence the transactivation of various target genes.
Our findings (summarized in Figure 7) provide strong evidence for
subtle but significant functional divergence in the intracellular
domains of mammalian Notch receptors.
The leukemogenicity of various ICN isoforms is correlated with
their ability to transactivate Myc, a direct Notch target gene in T-
ALL cells [39,40,41]. Myc provides important leukemogenic
signals, as ectopic Myc expression rescues growth and survival of
some, but not all, Notch-dependent human T-ALL cell lines when
Notch signaling is inhibited [45], and conditional deletion of Myc
impedes Notch1-dependent T-ALL development in mouse models
[46]. Notch1 transactivation of Myc has also been implicated in the
pathogenesis of other neoplasms, including murine mammary
tumors [47].
Although several possible CSL/ICN binding sites have been
identified near the proximal Myc promoter [39,40,41], additional
work is needed to determine how Notch1 transactivates Myc and
how ANK sequence variation influences this process. Some Notch
target genes are regulated by a sequence-paired-site (SPS), a
special ‘‘head to head’’ configuration of CSL binding sites that
permits the formation of dimeric CSL/ICN/MAML complexes
via interactions involving ANK [48]. Notably, dimerization
defective ICN1 mutants induce T cell development, but cannot
transactivate Myc, induce T-ALL or maintain T-ALL cell growth
[49], a phenotype resembling that produced by ICN4. Thus, one
possibility is that ICN4 fails to form functional dimeric trans-
cription complexes on a yet-to-be-discovered SPS that governs
Myc expression.
Three key residues involved in dimer contacts in ICN1 are
K1946,E1950,and R1985[48]. Theseresiduesvaryslightly among
the mammalian ICNs; for example, ICN4 has an arginine residue
instead of a lysine residue at the position analogous to K1946 in
ICN1. While studies in purified systems have not uncovered
substantial differences in the ability of ICN1-4 to form complexes
with CSL and MAML1 on DNA sequences containing single CSL
sites or high affinity SPSs [48,50], ICN4 might be unable to form
dimers on low-affinity, non-consensus, ‘‘cryptic’’ SPSs, which have
recently been identified near several direct Notch1 target genes
[48]. On the other hand, however, in 8946 cells the ICN1(ANK4)
Figure 6. Non-Leukemogenic Forms of ICN Fail to Rescue 8946 Cell Line Growth and do not Transactivate Myc. (A) Comparison of
rescue of 8946 cells by various ICN polypeptides following doxycycline-mediated withdrawal of MYC. 8946 cells were transduced with MigRI viruses,
sorted for GFP positivity, and then treated with doxycycline (20 microgram/ml) for up to 8 days. Cell numbers at each time point are shown. (B, C)
8946 cells transduced as in (A) were harvested after 24 hr of treatment with doxycycline (20 microgram/ml) or vehicle (PBS). Levels of Myc (B) and
Deltex1 (C) mRNAs were determined by qRT-PCR.
doi:10.1371/journal.pone.0025645.g006
Figure 7. Summary of Effects of ICNs on Induction of T Cell Development, Induction of T-ALL, and Myc Transactivation. The domain
organization of ICN chimeras is shown at left, and the ability of each to induce T cell development, induce T-ALL, and transactivate Myc is summarized
at right. n.d.=not determined.
doi:10.1371/journal.pone.0025645.g007
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tion-dependent Notch target that appears to be regulated by a
crypticSPS[49].AsecondpossibilityisthatICN4isfullycompetent
for dimer formation, but unable to recruit additional unknown
factors that are essential for transactivation of a subset of Notch
target genes, including Myc. Both ideas are in line with a structural
comparison of ANK1-4 (Figure S3), which shows that the most
divergent surface residues lie away from CSL/MAML contacts on
the backside of the ANK domains. This more divergent ANK
surface participates in dimerization and could also be involved in
differential recruitment of co-factors to Notch transcription
complexes. Testing of these possibilities awaits further character-
ization of the genetic elements involved in Notch regulation of Myc
and the biochemical composition of Notch transcription complexes.
The Notch pathway is an attractive therapeutic target in T-ALL
[51,52], but attempts to treat relapsed/refractory disease have
revealed that non-selective GSIs cause ‘‘on-Notch’’ toxicity by
skewing the differentiation of epithelial progenitors towards goblet
cell fate. The ability of Notch to function as a tumor suppressor
raises additional concerns about long-term toxicity associated with
Notch pathway blockade. A detailed biochemical comparison of
complexes formed by different Notch receptors (e.g., ICN1 and
ICN4) may reveal opportunities for development of therapies that
selectively interfere with the transactivation of subsets of Notch
target genes within particular cellular contexts, thereby obviating
toxicities associated with pan-Notch inhibitors.
Materials and Methods
Expression Plasmids
A cartoon depicting ICN1-4 is shown in Figure 1. The
constructs encoding ICN1 (amino acids 1759 to 2556) and
ICN2 (amino acids 1721 to 2471) have been described [53] The
cDNA encoding ICN3 (amino acids 1667 to 2318) was the kind
gift of Dr. Urban Lendahl. The ICN4 cDNA was created by PCR
amplification of a lambda phage gt11 human umbilical vein
endothelial cell cDNA library (the kind gift of Dr. David Ginsburg)
with ICN4-specific primers, and encodes amino acids 1472 to
2003 of human Notch4. Each cDNA was engineered to have an
ATG start codon within the same Kozak consensus sequence.
These cDNAs were cloned into the plasmid pcDNA3 (Invitrogen)
and the retroviral vector MigRI, which also contains an internal
ribosomal entry sequence and a cDNA encoding GFP. Chimeric
ICN cDNAs were created by introducing restriction sites by PCR
that permitted the ligation of cDNA fragments of interest followed
by site directed mutagenesis (QuikChange Kit, Stratagene). The
identities of all expression constructs were confirmed by DNA
sequencing. The specific points of joining that were used to create
chimeric ICNs and the alignment of the ICN1-4 RAM and ANK
domains are shown in Figure S1.
Cell Culture
Cell culture reagents were obtained from Invitrogen. U2OS and
293T cells were obtained from the American Type Culture
Collection. U2OS, 293T, and Bosc23 cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum, 2 mM L-glutamine, 100 U of
penicillin/ml, and 100 mg of streptomycin/ml. T6E cells and 8946
cells [39] were grown in RPMI 1610 media with the same
additions. Cell lines were grown at 37uC under 5% CO2.
Thymic Organ Culture
Harvest of fetal liver hematopoietic progenitor cells and seeding
of thymic organ cultures were as described [54]. Briefly, liver cells
from day 15 B6 fetal mice wereisolated on a Ficollgradient, washed
with PBS, and suspended at 1–2610
6 cells/ml in 2 ml of Iscove
Modified Dulbecco’s medium containing 10% fetal calf serum,
2 mM glutamine, 0.5 mM penicillin and streptomycin, 50 ng/ml
stem cell factor, 6 ng/ml interleukin-3, 4 ng/ml interleukin-1beta,
and 1 ng/ml interferon-gamma. The following day, the cells were
transduced with MigRI retroviruses and used to seed irradiated day
15 fetal thymic lobes (1610
5 cells/lobe) harvested from the same
fetuses in hanging drops. After 24 hr, reconstituted fetal thymic
lobes were placed on 0.8micron polycarbonate membranes
(Isopore) in the presence of absence of 1 microM compound E
(Tocris), a potent gamma-secretase inhibitor.
Murine Bone Marrow Transplantation
Animal care and experimental protocols were performed
according to guidelines from the National Institutes of Health
with an approved protocol (801264) from the Institutional Animal
Care and Use Committee at the University of Pennsylvania School
of Medicine. Mouse experiments were performed in the BRB II/
III animal facility at the University of Pennsylvania, which is
staffed by animal handlers that are experienced in the care of
rodents. Veterinarian services are available at the University of
Pennsylvania. A veterinarian reviews all IACUC protocols prior to
initiation of the study. The University Laboratory Animal
Resources and Department of Laboratory Animal Medicine
veterinarian makes regular inspections and provides veterinary
care. Every effort was made to reduce the level of pain or
discomfort in our studies. Mice were observed daily and when
abnormal conditions/behavior was observed, it was reviewed with
the attending veterinarian to determine the proper course of
action. When euthanasia was required, it was accomplished
according to the IACUC guidelines by exposure to carbon
dioxide, consistent with the recommendations of the Panel on
Euthanasia of the American Veterinary Medical Association.
Briefly, MigRI plasmids were packaged into ecotropic retrovi-
ruses by transient transfection of Bosc23 cells. Retroviral
supernatants were titered on NIH 3T3 cells using GFP as a
marker of transduction. Bone marrow cells from 5-fluoruracil-
treated female 4–8 week old C57BL/6 mice (Taconic Farms) were
transduced with GFP-normalized retroviral supernatants in
DMEM containing 10% heat-inactivated FBS (Invitrogen), 5%
WEHI-conditioned medium, 6 U/ml recombinant mouse IL-3
(Genzyme Corp., Cambridge, MA), 10,000 U/ml recombinant
murine IL-6 (Genzyme), 5 U/ml recombinant murine stem cell
factor (Genzyme), 4 microgram/ml polybrene (Sigma Chemical
Co., St. Louis, MO), 100 U/ml streptomycin (Invitrogen), 100 U/ml
penicillin (Invitrogen), and 2 mM L-glutamine (Invitrogen). Trans-
duced bone marrow cells were injected into lethally irradiated (900
rads) 4- to 8-week-old female syngeneic recipients.
Flow Cytometry
Peripheral blood samples and tumor cell suspensions were assessed
for GFP
+ immature T cells by flow cytometric analysis (Becton
Dickinson, FACSCalibur). Cells were incubated with PE-labeled
anti-CD8alpha (53–6.7), biotinylated anti-TCRbH57-597), and
APC-labeled anti-CD4 (RM4-5) antibodies (Pharmingen). Biotiny-
lated antibodies were revealed with streptavidin-PerCP. Dead cells,
identified by forward and side scatter, were excluded from the
analysis. FACS results were analyzed using CellQuest software.
Cell Cycle Analyses
Analyses were carried out as described [39]. Live or fixed cells
were stained with Hoechst 33342 (4 microM, Sigma B2261) or
propidium iodide (40 microgram/ml), respectively, and then
Notch Receptor Functional Variation
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Data analysis was performed using FlowJo software (Treestar).
Reporter Gene Assays
Notch1 expression plasmids were introduced into U2OS cells by
transient transfection with Lipofectamine Plus (Invitrogen) and
assessed for their ability to activate an artificial Notch-sensitive
reporter gene as described [18]. Briefly, cells in 24-well dishes were
co-transfected with 1 ng or 10 ng of various pcDNA3-Notch
expression constructs, a Notch-sensitive firefly luciferase reporter
gene, and an internal control pRL-TK Renilla luciferase gene
(Promega). Total transfected DNA was kept constant by adding
empty pcDNA3 plasmid. Normalized firefly luciferase activities
were measured in whole cell extracts prepared 44–48 hr after
transfection using the Dual Luciferase kit (Promega) and a
specially configured luminometer (Turner Systems).
Protein purification
ANK1-4 polypeptides were expressed and purified as described
[55]. BL21 (DE3) pLysS Escherichia coli were transformed with the
appropriate plasmids and grown at 37uC in LB medium with
100 mg/mL ampicillin and 34 mg/mL chloramphenicol to an
OD600 of 0.7–0.9. Protein expression was induced with 1 mM
isopropyl-1-thio-b-D-galactopyranoside (IPTG) for 4 hr, and cells
were harvested by centrifugation at 3500 rcf for 30 minutes. Pellets
were frozen at 280uC after resuspension in 20 mL lysis buffer
(50 mMTrispH 8.0,300 mMNaCl) perliterculture.Afterthawing
in the presence of protease inhibitors (Complete, Roche), 5 mM b-
mercaptoethanol, and 1 mM EDTA, cells were lysed by sonication
and the clarified lysate was applied to glutathione-agarose beads
(Sigma-Aldrich). Beads were washed with buffer A (50 mM Tris,
pH 8.0, 150 mM NaCl, 5 mM DTT) and incubated with
approximately 200 ng of tobacco etch virus (TEV) protease per
3 mL pelleted beads for 12–16 hr at room temperature. Following
removal of theprotease byapplicationofthe supernatant to Ni-NTA
resin (Qiagen), ANK molecules were further purified by anion-
exchangechromatography on a MonoQ10/100GLcolumnusing a
linear gradient from 0.1–0.6 M NaCl in 20 mM Tris, pH 8.0,
5 mMDTT,1 mMEDTAand size-exclusion chromatographyona
Superdex S200 16/60 column in 20 mM Tris pH 7.5, 150 mM
NaCl, 5 mM DTT. Proteins were concentrated to 5–10 mg/mL,
aliquoted, flash frozen in liquid nitrogen, and stored at 280uC.
Circular Dichroism Spectrocopy
CD spectra were acquired on an AVIV 62DS spectropolarimeter
with proteins in 10 mM phosphate buffer at 5 to 10 mM for 1 mm
path length cuvettes and 0.5–1 mM for 1 cm path length cuvettes.
Concentrations were determined by absorbance at 280 nm [56].
Wavelength scans were performed at 4uC in a 1 mm path length
cuvette using a 1 nm step size, a 3-second averaging time, and 5
repeats. Thermal melts were performed by monitoring the CD
signal at 222 nm in a 1 cm path length cuvette and varying the
temperature from 4uCt o8 0 uC with a thermoelectric temperature
controller, using a 2-minute equilibration period, a 1uC step size,
and a 30-second acquisition time. Approximate melting tempera-
tures were determined by fitting the thermal denaturation curves
with the program IgorPro (Wavemetrics).
Quantitative Reverse Transcriptase Polymerase Chain
Reaction (qRT-PCR) Assays
Expression levels of the Notch target genes Myc, Deltex1, Trb2,
Notch3, CD25, and Ptcra were determined by qRT-PCR as
described [39,57].
Pathology
At necropsy, tissues were i) fixed in formalin and embedded in
paraffin for histologic analysis, or ii) disaggregated for flow
cytometry or injection into secondary recipients. Paraffin sections
were stained with hematoxylin and eosin.
Supporting Information
Figure S1 Multi-sequence alignment of ICN1-4. The
aligned sequences correspond to the RAM and ANK domains of
ICN1-4. Hydrophobic residues are colored red, hydrophilic
residues are colored green, basic residues are colored magenta,
and acidic residues are colored blue. AN and AC designate the N-
terminal and C-terminal boundaries of the crystallized ANK
domain of Notch1 (residues 1873–2127), while AS brackets the
region of ANK that is structured (residues 1909–2123). J1 and J3
designate points of joining in chimeras in which entire ANK
domains were swapped; J2 and J3 are points of ANK repeat 2–7
only swaps; while J3 is the point of joining in C-terminal sequences
swaps. *=identical residues; :=conservative substitutions; .=semi-
conservative substitutions.
(TIF)
Figure S2 Circiular Dichroism Spectra and Thermal
Stability of the Notch1-4 Ankyrin Repeats. The four ANK
molecules do not demonstrate heterogeneity in overall secondary
structure characteristics. (A) Circular dichroism scans of the four
domains at 4uC. (B) Temperature dependence of the CD signal at
222 nm for the four domains, with an apparent Tm between 46uC
and 50uC for each ANK.
(TIF)
Figure S3 Conservation of Surface Residues in the
Notch1-4 Ankyrin Repeats. The ANK domain of human
Notch1 (pdb ID code 2F8Y) was rendered as a molecular surface
using the program PyMol (DeLano Scientific). The inner concave
and outer convex surfaces of the ANK domain are shown alone in
the top two panels, and in the context of the ternary complex with
MAML1 and CSL in the lower panels; ‘‘1’’ and ‘‘7’’ designate the
amino- and carboxy-terminal ankyrin repeats 1 and 7, respective-
ly. The ANK surface is colored according to sequence conserva-
tion among the ANK domains of Notch1-4 on a sliding scale from
dark blue (100% conserved) to red (least conserved).
(TIF)
Figure S4 ICNs have no Effect on 8946 Cell Growth
when Transgenic MYC is ‘‘On’’. 8946 cells were transduced
with empty MigRI or the indicated forms of ICN1 and monitored
for growth in the presence of vehicle only (DMSO).
(TIF)
Figure S5 Effect of Various ICNs on Notch Target Gene
Expression in 8946 Cells. 8946 cells transduced with the
indicated MigRI viruses were sorted for GFP positivity, harvested
after 24 hr of treatment with doxycycline (20 microgram/ml) or
vehicle (PBS), and analyzed for expression of the various Notch
target genes.
(TIF)
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